Chavez, MD, discusses how comprehensive genomic profiling may impact the treatment and clinical management of patients with small cell lung cancer.

The FDA granted priority review to a new drug application for sunvozertinib as an oral treatment for certain patients with ...

Scientists have developed inhalable lung cancer therapeutics utilizing mucoadhesive proteinic nanoparticles.

Edgardo S. Santos, MD, FACP, FASCO, emphasized the need to eliminate the stigma around smoking in lung cancer, highlighted the importance of early detection and discussed how advances in precision ...

Oct. 9, 2024 — Researchers have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 ... Scientists Discover That ...

Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year ...

Small-cell lung cancer is one of the most aggressive types of cancer. It represents about 10 to 15 percent of all lung cancer cases in the United States, with roughly 30,000 to 35,000 new cases ...

Dec. 19, 2024 – The FDA has approved a new drug called ensartinib for adults with a type of lung cancer called ALK-positive non-small-cell lung cancer (NSCLC). Sold under the brand name ...

Instead, Google seemed to love reminding me about the bleak prognosis for non-small-cell lung cancer, which I have, and how poorly funded it remains vs. other major cancers, despite it being the ...

“Bev has significant kyphoscoliosis (curvature of the spine that’s both sideways and forward/backward), which made the biopsy ...